Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F. Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. World J Gastrointest Oncol 2019; 11(8): 634-641 [PMID: 31435464 DOI: 10.4251/wjgo.v11.i8.634]
Corresponding Author of This Article
François Ghiringhelli, MD, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2019; 11(8): 634-641 Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
Valeria Basso, David Orry, Jean Fraisse, Julie Vincent, Audrey Hennequin, Leila Bengrine, Francois Ghiringhelli
Valeria Basso, David Orry, Jean Fraisse, Department of Surgery, Centre Georges Francois Leclerc, Dijon 21000, France
Julie Vincent, Audrey Hennequin, Leila Bengrine, Francois Ghiringhelli, Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon 21000, France
Author contributions: Basso V collected clinical data; Orry D and Ghiringhelli F designed the study; Orry D, Fraisse J, Vincent J, Hennequin A and Ghiringhelli F treated patients includes in this study; Ghiringhelli F analyzed the data; Ghiringhelli F and Basso V wrote the manuscript; All authors have read and approve the final manuscript.
Informed consent statement: Written informed consent form was provided by family members of the patients.
Conflict-of-interest statement: All authors have no conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: François Ghiringhelli, MD, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr
Telephone: +33-380-732424 Fax: +33-380-737500
Received: March 18, 2019 Peer-review started: March 20, 2019 First decision: June 4, 2019 Revised: June 7, 2019 Accepted: June 20, 2019 Article in press: June 20, 2019 Published online: August 15, 2019
ARTICLE HIGHLIGHTS
Research background
Localized oeso-gastric cancer (GC) are treated by perioperative chemotherapy and surgery. The use of taxane seems to improve response rate and outcome.
Research motivation
Only the efficacy of the german regimen FLOT was previously reports.
Research objectives
To determine the efficacy of the Frence TeFOX regimen.
Research methods
This retrospective study aims to test efficacy and safety of the perioperative TeFOX regimen given alone in patients with localized GC.
Research results
Thirty-three consecutive patients were included. Median follow-up of surviving patients was 32 mo. R0 resection was obtained in 30 (91) patients. Twelve patients (36) have a pathological complete response and 8 (24) patients a nearly complete pathological response.
Research conclusions
TeFOX regimen could be safely administrated in perioperative treatment of localized GC.
Research perspectives
TeFOX and the FLOT regimen have comparable efficacy and safety profiles and could be considered as an alternative regimen.
